How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
|Articles|January 6, 2022
Clinical Pearl of the Day: Generalized Anxiety Disorder
Author(s)Saro Arakelians, PharmD
Generalized anxiety disorder has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety.
Advertisement
Clinical Pearl of the Day: Generalized Anxiety Disorder (GAD)
Patients with GAD experience continuous anxiety and stressful life experience.
Insight:
- It's possible to develop GAD as a child or an adult.
- GAD has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety, but they're all different conditions.
- Living with generalized anxiety disorder can be a long-term challenge.
- In many cases, GAD occurs along with other anxiety or mood disorders.
- In most cases, GAD improves with psychotherapy or medications.
- Symptoms may include persistent worrying, overthinking, indecisiveness, inability to relax, and difficulty concentrating.
- Risk factors may include genetics and life experiences.
- Diagnosis may include physical therapy and mental assessment.
- Treatment includes psychotherapy, antidepressants, buspirone, and benzodiazepines.
- Making lifestyle changes, learning coping skills, and using relaxation techniques also can help.
Sources:
Advertisement
Related to this article
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Glucose Monitoring: Timing Makes Every Reading Count
2
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
3
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
4
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
5